Verve PCSK9-inhibitor gene therapy
Tracked across 1 events · 12 articles · First seen May 26, 2026 · Last active Jun 07, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Tech
Scientists have reported promising results from a groundbreaking gene-editing therapy, VERVE-102, developed by Verve PCSK9-inhibitor gene therapy>>>, a subsidiary of Eli Lilly and Company>>>. This therapy aims to permanently reduce 'bad' cholesterol (LDL cholesterol) after…
Impact: Verve PCSK9-inhibitor gene therapy>>> developed VERVE-102, a groundbreaking gene-editing therapy for high cholesterol. The positive results from its Phase 1b clinical trial are a major success for the company, potentially leading to a new era in cardiovascular disease prevention.
May 26, 2026 · 12 articles
100
Verve PCSK9-inhibitor gene therapy developed therapyVERVE-102 Gene Edit Lowers...
95
Verve PCSK9-inhibitor gene therapy conducted clinical trialVERVE-102 Gene Edit Lowers...
80
United States — Food and Drug Administration granted Fast Track designation Verve PCSK9-inhibitor gene therapyVERVE-102 Gene Edit Lowers...
NEWSDESK
Track Verve PCSK9-inhibitor gene therapy live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard